Biosante Pharmaceuticals (BPAX)
Add to Watchlists Create an AlertBPAX Key Stats
| Income Statement | |
| Revenue TTM | 2.301M |
| Revenue Quarterly YoY Growth | 1620% |
| EPS Diluted TTM | -1.333 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -27.72M |
| Profitability | |
| Gross Profit Margin Quarterly | 95.17% |
| Profit Margin Quarterly | -202.7% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 27.84M |
| Enterprise Value | 0.9312M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 0.9882 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.2798 |
| Free Cash Flow | -3.247M |
| Return on Equity | -82.89% |
BPAX News
- BioSante Pharmaceuticals, Inc. Reports First Quarter Financial Results Business Wire May 10
- BIOSANTE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Finan... May 10
- BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Special Meetings of St... May 8
- Huge Potential But Tough Entry For Female Sexual Dysfunction Drugs May 7
- 4 Bio Stocks to Buy Today May 1
- Ceregene Reports Disappointing Top-Line Data From Parkinson's Disease Phase 2b S... Apr 19
- Ceregene Reports Data From Parkinson's Disease Phase 2b Study PR Newswire Apr 19
- BioSante Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. Announce New Merger... Apr 13
- BioSante Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. Announce New Merger... Apr 12
- BIOSANTE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitiv... Apr 12
BPAX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Biosante Pharmaceuticals is down 58.79% over the last year vs S&P 500 Total Return up 28.68%, Repros Therapeutics up 98.72%, and Teva Pharmaceutical Industries up 3.39%.
BPAX Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these BPAX related companies
Pro Ratings for BPAX
Pro Report PDF for BPAX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download BPAX Pro Report PDF
Pro Strategies Featuring BPAX
Did Biosante Pharmaceuticals make it into our Pro Portfolio Strategies?
BPAX Profile
Sector: Healthcare
Industry: Biotechnology
Other BPAX Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BPAX | 1.14 | -0.01 | -0.87% | 27.84M |
